SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01456650

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus

The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes.

NCT01456650 Type 2 Diabetes
MeSH:Diabetes Mellitus, Type 2
HPO:Type II diabetes mellitus

1 Interventions

Name: Glyburide

Description: Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table: Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening.
Type: Drug
Group Labels: 1

Glyburide


Primary Outcomes

Description: The effects of the alleles under study on the glucose lowering effect of glyburide will be assessed in 20 week study. Diet and exercise will be controlled per protocol

Measure: Change in plasma fasting glucose

Time: 20 weeks

Secondary Outcomes

Measure: HbA1c levels

Time: 20 weeks

Purpose: Basic Science

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 R230C

Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus. --- R230C ---

R230C and C230C Variants of ABCA1 and Glyburide Response The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes. --- R230C ---

R230C and C230C Variants of ABCA1 and Glyburide Response The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes. --- R230C --- --- R230C ---

In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following continuous variables: - Fasting glucose - Percentage reduction - Hemoglobin A1c, - Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol - Weight 2. In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following binomial variables: - Number of cases that reach fasting plasma glucose lower than 110 mg/dl - Number of cases that reach an HbA1c less than 7% --- R230C ---

In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following continuous variables: - Fasting glucose - Percentage reduction - Hemoglobin A1c, - Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol - Weight 2. In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following binomial variables: - Number of cases that reach fasting plasma glucose lower than 110 mg/dl - Number of cases that reach an HbA1c less than 7% --- R230C --- --- R230C ---



HPO Nodes


HPO: